Nisa Investment Advisors LLC Decreases Stake in Organon & Co. (NYSE:OGN)

Nisa Investment Advisors LLC lessened its holdings in shares of Organon & Co. (NYSE:OGN) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,640 shares of the company’s stock after selling 11,225 shares during the period. Nisa Investment Advisors LLC’s holdings in Organon & Co. were worth $1,217,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in shares of Organon & Co. by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after purchasing an additional 192,613 shares during the last quarter. LSV Asset Management boosted its stake in Organon & Co. by 47.3% during the second quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after buying an additional 2,121,940 shares during the last quarter. Nordea Investment Management AB grew its holdings in Organon & Co. by 26.9% in the 1st quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company’s stock valued at $74,563,000 after buying an additional 841,518 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Organon & Co. by 39.8% in the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after acquiring an additional 988,336 shares during the last quarter. Finally, Deprince Race & Zollo Inc. raised its holdings in shares of Organon & Co. by 6.8% during the 2nd quarter. Deprince Race & Zollo Inc. now owns 3,421,703 shares of the company’s stock worth $70,829,000 after acquiring an additional 216,907 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on OGN shares. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their price objective for the stock from $18.00 to $20.00 in a research report on Friday, September 6th. Evercore ISI upgraded shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th.

Organon & Co. Stock Down 3.8 %

Shares of NYSE:OGN opened at $18.07 on Monday. The business has a 50-day moving average price of $19.38 and a 200 day moving average price of $20.13. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.65 billion, a price-to-earnings ratio of 3.59, a PEG ratio of 0.85 and a beta of 0.84. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.04. The company had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 2,437.43%. Organon & Co.’s revenue was down .1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.31 earnings per share. Sell-side analysts expect that Organon & Co. will post 4.04 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 6.20%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.’s payout ratio is 22.22%.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.